scispace - formally typeset
R

Robert Silber

Researcher at New York University

Publications -  120
Citations -  5671

Robert Silber is an academic researcher from New York University. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 39, co-authored 120 publications receiving 5619 citations. Previous affiliations of Robert Silber include Columbia University & Yale University.

Papers
More filters
Journal ArticleDOI

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

Beppino C. Giovanella, +7 more
- 24 Nov 1989 - 
TL;DR: Unlike other anticancer drugs tested, 20(RS)-9-amino-camptothecin (9-AC) induced disease-free remissions and the overall drug toxicity was low and allowed for repeated courses of treatment.
Journal ArticleDOI

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

S el Rouby, +6 more
- 01 Dec 1993 - 
TL;DR: P53 gene mutations in B-CLL are associated with a poor clinical outcome and may be a prognostic indicator for drug resistance, and the possible role of p53 gene regulation in the expression of the multidrug resistance genes MDR1 and MDR3 is investigated.
Journal Article

DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.

Annette L. Bodley, +8 more
- 01 Nov 1989 - 
TL;DR: The study shows that DNA intercalation is required but not sufficient for the activity by topo-II-targeted anthracyclines, and may provide guidance for the synthesis and development of new active analogues.
Journal Article

Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.

Yeou-Ping Tsao, +4 more
- 15 Dec 1993 - 
TL;DR: It is proposed that one or several of these events triggers S-phase-specific cell killing and G2-phase cell cycle arrest and the interaction between an advancing replication fork and a topoisomerase I-camptothecin-DNA-cleavable complex results in irreversible arrest of the replication fork.
Journal Article

Complete Growth Inhibition of Human Cancer Xenografts in Nude Mice by Treatment with 20-(S)-Camptothecin

Beppino C. Giovanella, +5 more
- 01 Jun 1991 - 
TL;DR: CAM is substantially more effective and less toxic than its sodium salt, which was unsuccessfully tested in cancer patients and should be further tested against responsive cancers as a drug which is easy to isolate and formulate for large-scale studies.